By Peter Loftus
Moderna shares fell 3% in premarket trading after the company swung to a quarterly loss, as fading demand for its Covid-19 vaccine hurts sales.
The company reported a net loss of $1.1 billion, or $2.91 per share, which included costs to end a contract manufacturing deal and an inventory writedown. A year earlier, Moderna earned $217 million, or 55 cents a share.
The company's fourth-quarter sales slid 65% to $966 million.
Moderna's share of the Covid-19 vaccine market declined in 2024, and overall vaccination rates were somewhat lower than the year before, Chief Financial Officer Jamey Mock said in an interview.
Moderna is in cost-cutting mode as revenue declines, but the company hopes to turn things around with newer products.
It is trying to broaden usage of its new respiratory syncytial virus vaccine, and has applied for U.S. regulatory approval of a next-generation Covid vaccine and a combination Covid-influenza shot, with decisions expected later this year.
This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL (WSJ Live Coverage).
(END) Dow Jones Newswires
February 14, 2025 08:18 ET (13:18 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。